Results 71 to 80 of about 16,268 (199)

Treatment of infections caused by multidrug-resistant Gram-negative bacteria:Report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party [PDF]

, 2018
The Working Party makes more than 100 tabulated recommendations in antimicrobial prescribing for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) and suggest further research, and algorithms for hospital and ...
Enoch, David A, Hawkey, Peter M, Livermore, David M, McNulty, Cliodna A M, Otter, Jonathan A, Warren, Roderic E, Wilson, A Peter R   +6 more
core   +1 more source

Effects of Nacubactam and Its Metabolites on QTc Interval: A Pooled Analysis of Two Randomized Phase 1 Studies

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Nacubactam is a β‐lactamase inhibitor. Early‐phase studies with 1000/2000/4000/8000 mg nacubactam monotherapy were not powered to assess proarrhythmic risk. Therefore, this analysis pooled electrocardiogram data from two placebo‐controlled studies to quantify potential effects of nacubactam on cardiac repolarization.
Jun Morita, Sue McKendrick, Yuji Kumagai
wiley   +1 more source

A Selective Medium for Screening Ceftazidime/Avibactam Resistance in Carbapenem-Resistant Enterobacterales

Frontiers in Microbiology, 2022
Ceftazidime/avibactam (CZA) is an alternative antibiotic used for the treatment of infections caused by carbapenem-resistant Enterobacterales (CRE). However, the CZA-resistant CRE strains have been detected worldwide.
Weiliang Zeng, Wenli Liao, Wenli Liao, Yajie Zhao, Lingbo Wang, Hongyun Shu, Huaiyu Jia, Tao Chen, Ying Zhang, Tieli Zhou, Qing Wu   +10 more
doaj   +1 more source

Antimicrobial Resistance (AMR) and Multidrug Resistance (MDR): Overview of Current Approaches, Consortia and Intellectual Property Issues [PDF]

, 2017
The supply of new diagnostics and treatments is insufficient to keep up with the increase in antimicrobial resistance (AMR) and multidrug resistance (MDR) as older medicines are used more widely and microbes develop resistance to them.
Bhagwandin, Niresh, Jenner, Andrew, Kowalski, Stanley P.   +2 more
core   +1 more source

Zwitterionic Penicillin‐Derived Sulfone Inhibitor for Combating β‐Lactamase‐Mediated Antibiotic Resistance

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez, Emilio Lence, Juan C. Vázquez‐Ucha, Alejandro Beceiro, Concepción González‐Bello   +4 more
wiley   +1 more source

New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections

Antibiotics
Nosocomial central nervous system (CNS) infections with carbapenem- and colistin-resistant Gram-negative and vancomycin-resistant Gram-positive bacteria are an increasing therapeutic challenge. Here, we review pharmacokinetic and pharmacodynamic data and
Roland Nau, Jana Seele, Helmut Eiffert
doaj   +1 more source

Activity of OP0595-β-lactam combination against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactama [PDF]

, 2015
Background: OP0595 is a diazabicyclooctane that (i) acts as a PBP2-ctive antibacterial, (ii) inhibits Class A and C β-lactamases and (iii), like mecillinam, gives β-lactamase-independent potentiation of β-lactams targeting other PBPs.
Livermore, David M., Mushtaq, Shazad, Warner, Marina, Woodford, Neil   +3 more
core   +1 more source

Evaluation of FilmArray Multiplex PCR Test Results in Bloodstream Infections in Oncological Patients

Journal of Clinical Laboratory Analysis, Volume 40, Issue 9, May 2026.
In this study conducted at an oncology hospital, BCID2 panel results for the rapid identification of microorganisms and resistance genes in positive blood culture samples were compared with conventional culture methods. The BCID2 panel provided faster results and showed a high correlation with traditional methods.
İpek Mumcuoğlu, Sevgi Şahin, Esra Tavukcu, Neşe İnan, Ayşe Semra Güreser, Serap Süzük Yıldız, Tuba Dal   +6 more
wiley   +1 more source

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC- producing Enterobacteriaceae [PDF]

, 2018
Introduction: Difficult Gram-negative infections are increasingly treated with new β-lactamase inhibitor combinations, e.g. ceftazidime/avibactam.
Doumith, Michel, Jamrozy, Dorota, Livermore, David M., Mushtaq, Shazad, Nichols, Wright W., Woodford, Neil   +5 more
core   +1 more source

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]

, 2020
Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Adedoyin, Adedayo, Caro, Luzelena, De Waele, Jan, Gadzicki, Elaine, Kuti, Joseph L, Larson, Kajal B, Nicolau, David P, Rhee, Elizabeth G, Yu, Brian, Zeng, Zhen   +9 more
core   +1 more source